Agapejev S, Da Silva M D, Ueda A K
Department of Neurology and Psychiatry, State University of São Paulo, UNESP, Brasil.
Arq Neuropsiquiatr. 1996 Mar;54(1):82-93. doi: 10.1590/s0004-282x1996000100014.
Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs. Multiple symptoms were observed in 90.9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.
对22例重症神经囊尾蚴病患者进行研究,给予阿苯达唑(ABZ)治疗,剂量为15至30mg/kg/天,共21至60天,分6种不同给药方案。辅助药物为右氯苯那敏和酮洛芬。90.9%的患者出现多种症状。90.9%的患者表现为颅内高压。86.4%的患者发生脑积水。10例患者病情转归良好,8例死亡,4例有后遗症。断层扫描研究显示,9例患者出现孤立的第四脑室,其中3例在脑室腹腔分流术后、ABZ治疗前出现,5例在治疗期间出现,1例在治疗后出现。死亡患者的中位临床随访时间为10个月,存活患者为3至4年。3例患者在给予15mg/kg/天ABZ剂量时囊肿大小增加,而使用30mg/kg/天剂量时未在任何患者中观察到这种情况。